Dernières nouvelles pour Rubrik (NYSE:RBRK) Stock

RUBRIK INC-A

Rubrik

Rubrik Inc is a company that offers data security solutions to organizations ranging from the largest companies world-wide to mid-sized smaller customers. Its platform is architected to help organizations achieve cyber resilience, which encompasses cyber posture and cyber recovery. It enables organizations to confidently accelerate digital transformation and leverage the cloud to realize business agility. Geographically, the company operates in the Americas, EMEA (Europe, the Middle East, and Africa) and APAC (Asia Pacific). It generates maximum revenue from Americas.

Rubrik Inc

- Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ("MDD") with expected combined enrollment of approximately 550 participants across three studies (APPROACH&#x2122;, EMBRACE&#x2122;, and EXTEND) -
- Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company's commercialization and manufacturing capabilities -
- Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin's clinical-stage pipeline -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=54274168&amp;newsitemid=20250612856093&amp;lan=en-US&amp;anchor=Cybin+Inc.&amp;index=1&amp;md5=b33e5f4a2662caf8115f1c9d66a66bc8">Cybin Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update.

News

CYBN

Cybin Announces Patient Dosing In Phase 3 CYB003 PARADIGM Program In Major Depressive Disorder With Expected Combined Enrollment Of About 550 Participants Across Three Studies

BRTX

BioRestorative Reports Preliminary Data For FDA-Fast-Tracked BRTX-100, An Autologous Stem Cell Therapy To Treat Chronic Lumbar Disc Disease; Says Updated Data Presented At ISSCR 2025 Demonstrates >50% Improvement In Pain And Function In Significant Portion Of cLDD Subjects

The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Clearone Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRO#NASDAQ">CLRO</a>)</h3>
<ul class="wp-block-list">
<li>On June 2, ClearOne announced it authorized a 1-for-15 reverse stock split. The company's stock fell around 27% over the past month and has a 52-week low of $4.35.</li>
<li>RSI Value: 17.9</li>
<li>CLRO Price Action: Shares of Clearone gained 1.6% to close at $5.80 on Thursday.</li>
<li>Edge Stock Ratings: 0.63 Momentum score with Value at 82.24. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/CLRO"><img loading="lazy" decoding="async" width="405" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13003541/image-207.png" alt="" class="wp-image-948444" style="width:338px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13003541/image-207.png 405w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13003541/image-207-300x135.png 300w" sizes="(max-width: 405px) 100vw, 405px" /></a></figure>
<h3 class="wp-block-heading">Cloudastructure Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 15, Cloudastructure reported $738.00 thousand in sales for the first quarter. &#8220;Cloudastructure began 2025 with substantial momentum,&#8221; said James McCormick, Chief Executive Officer of Cloudastructure. &#8220;Revenue for the quarter more than tripled year-over-year, we turned the corner on gross profit, and we secured the largest contract in our Company&#8217;s history. The demand for real time crime deterrence has never been stronger—and we are leading the charge.&#8221; The company's stock fell around 40% over the past month and <a href="https://www.benzinga.com/quote/CSAI">has a 52-week low</a> of $1.91.</li>
<li>RSI Value: 26.6</li>
<li>CSAI Price Action: Shares of Cloudastructure closed at $2.00 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0613">CSAI stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0613"><img loading="lazy" decoding="async" width="915" height="820" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13004932/image-209.png" alt="" class="wp-image-948448" style="width:673px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13004932/image-209.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13004932/image-209-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13004932/image-209-768x688.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<h3 class="wp-block-heading">Digital Ally Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>)</h3>
<ul class="wp-block-list">
<li>On May 21, Digital Ally reported a year-over-year decrease in first-quarter sales results. &#8220;Our first quarter financial results, which included substantial non-operating gains and losses, clearly reflect the operating leverage inherent in our business model that has resulted from substantial decreases in overhead expenses, reduced headcount, and the focus on our subscription based sales model for our video solutions segment and the successful restructuring of our law enforcement products sales organization,&#8221; stated Stanton E. Ross, Chief Executive Officer of Digital Ally, Inc. The company's stock fell around 29% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/DGLY">low of $1.93</a>.</li>
<li>RSI Value: 25.9</li>
<li>DGLY Ltd Price Action: Shares of Digital Ally fell 3.2% to close at $2.84 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0613">DGLY shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0613"><img loading="lazy" decoding="async" width="888" height="848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13005047/image-210.png" alt="" class="wp-image-948450" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13005047/image-210.png 888w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13005047/image-210-300x286.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13005047/image-210-768x733.png 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>.
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45902941/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-q2">Top 2 Defensive Stocks That May Keep You Up At Night In Q2</a></li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

CLRO

CSAI

DGLY

Top 3 Tech Stocks That Are Preparing To Pump This Quarter

Benchmark analyst Cody Acree reiterates Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and maintains $170 price target.

Price Target

Reiteration

Analyst Ratings

Benchmark Reiterates Buy on Advanced Micro Devices, Maintains $170 Price Target

Rosenblatt analyst Hans Mosesmann maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and maintains $200 price target.

Rosenblatt Maintains Buy on Advanced Micro Devices, Maintains $200 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $50 price target.

CLDX

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $50 Price Target

Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and maintains $95 price target.

Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $95 Price Target

Needham analyst Joshua Reilly reiterates Bandwidth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAND#NASDAQ">BAND</a>) with a Buy and maintains $20 price target.

BAND

Needham Reiterates Buy on Bandwidth, Maintains $20 Price Target

Rosenblatt analyst Mike Genovese maintains Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) with a Buy and raises the price target from $18 to $20.

EXTR

Rosenblatt Maintains Buy on Extreme Networks, Raises Price Target to $20

&nbsp;
Two months ago I gave Iran a 60 day ultimatum to "make a deal." They should have done it! Today is day 61. I told them what to do, but they just couldn't get there. Now they have, perhaps, a second chance!
&nbsp;
&nbsp;

Macro Economic Events

Global

Economics

iShares MSCI Israel Capped Investable Market Index Fund

President Trump Posts On Truth Social: 'Two months ago I gave Iran a 60 day ultimatum to "make a deal." They should have done it! Today is day 61. I told them what to do, but they just couldn't get there. Now they have, perhaps, a second chance!'

Barrington Research analyst Gary Prestopino maintains PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) with a Outperform and maintains $15 price target.

AIOT

Barrington Research Maintains Outperform on PowerFleet, Maintains $15 Price Target

Texas is the second‑most populous state2 in the U.S. and recorded over 323,000 home sales in 2024, with a median sale price of $347,000, representing more than $112 billion in residential transaction value3. This expansion into Texas positions reAlpha to reach millions of prospective homebuyers through a tech-enabled, streamlined platform that delivers real savings at closing, including in high-volume markets such as Dallas-Fort Worth, San Antonio, Houston, and Austin.
 &nbsp;

AIRE

reAlpha Tech Enters Texas Market With Launch Of AI-Driven Real Estate Brokerage Services

<a href="https://www.globenewswire.com/Tracker?data=sRJiU6AhBwRs7N2q0k9SUJED5c2NDl4SjhSsHUwYHRP4meEtNPhrehANOUDTP0kRW6urx4bwssPhRWmHGPipsA==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association's (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD).
Details for the oral presentation are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Session Title:</td>
<td>Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies – Take 1</td>
</tr>
<tr>
<td>Session Date/Time:</td>
<td>Saturday, June 21, 2025, 4:30 PM - 6:00 PM CDT</td>
</tr>
<tr>
<td>Presentation Title:</td>
<td>Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight</td>
</tr>
<tr>
<td>Presenter:</td>
<td>John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Saturday, June 21, 2025 at 5:45 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
Details of the poster presentations are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment (poster #749-P)</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Shaheen Tomah, M.D., Director, Clinical Development, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Sunday, June 22, 2025, 12:30 PM - 1:30 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Non-invasive Tests of Central Adiposity Correlate with Reductions in MRI-measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide (poster #748-P)</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Shaheen Tomah, M.D., Director, Clinical Development, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Sunday, June 22, 2025, 12:30 PM - 1:30 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model (poster #778-P)</td>
</tr>
<tr>
<td>Presenter:</td>
<td>John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Sunday, June 22, 2025, 12:30PM - 1:30 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Altimmune to Present Data on Obesity and Liver Drug Pemvidutide at Upcoming Diabetes Conference

Phillips Edison &amp; Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PECO#NASDAQ">PECO</a>) ("PECO" or the "Company"), one of the nation's largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced that its operating partnership, Phillips Edison Grocery Center Operating Partnership I, L.P. (the "Operating Partnership"), has priced a public offering of $350 million aggregate principal amount of 5.250% senior unsecured notes due 2032 (the "Notes"). The Notes were priced at 99.832% of the principal amount and will mature on August 15, 2032. The offering is expected to settle on June 17, 2025, subject to the satisfaction of customary closing conditions. The notes will be fully and unconditionally guaranteed by PECO.
The Operating Partnership intends to use the net proceeds from the offering for general corporate purposes, including to repay borrowings under its revolving credit facility, to repay its term loans and other outstanding indebtedness, to acquire additional properties, for capital expenditures, expansion and working capital, to redevelop and/or improve properties and for other general corporate purposes. Pending application of the net proceeds from the offering for the foregoing purposes, such proceeds may initially be invested in short-term securities.

PECO

Phillips Edison's Operating Partnership Prices Public Offering Of $350M Aggregate Principal Amount Of 5.250% Senior Unsecured Notes Due 2032

ASTS

AST SpaceMobile Settles Term Sheet Facilitating Long-Term Access To Up To 45 MHz Of Premium Lower Mid-Band Spectrum In North America For Direct-to-Device Satellite Applications

Sensei Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding shares of common stock ("Reverse Stock Split"), effective at&nbsp;5:00 p.m. Eastern Time&nbsp;on&nbsp;June 16, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on&nbsp;May 21, 2025, with the final ratio subsequently determined by the Company's Board of Directors. The reverse stock split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on Tuesday,&nbsp;June 17, 2025&nbsp;under the Company's existing trading symbol "SNSE" with the new CUSIP number 81728A207.

Stock Split

SNSE

Sensei Biotherapeutics To Implement 1-For-20 Reverse Stock Split Of Issued And Outstanding Shares, Effective June 16, 2025

Senmiao Technology Limited ("Senmiao" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/AIHS#NASDAQ">AIHS</a>), a financing and servicing company focused on the online ride-hailing industry in China, today announced that it has signed a strategic cooperation agreement (the "Agreement") with <a href="https://www.globenewswire.com/Tracker?data=JVw778hMIeG3PerOje-sevKZsnS-KaGXq6E6ME5yrktKIa1u6LtMSnlJUCJ0TEFm5fbR1E2ej7GGHMvmvfdJHkfacsuagMlltv-51zSUR8O0BAZ0bWw-g_b2pnrSZrvpSTR-GQsgbBMEPtYd3q0-aA==">Changsha Yipeng Information Technology Co., Ltd</a>. ("Changsha Yipeng") to jointly develop an AI-backed data management system aiming to improve efficiency of online ride-hailing management platforms.
Changsha Yipeng has over a decade of experience in developing integrated AI-based information systems, big data, and cloud platforms for government and private entities in China, across a variety of sectors.
Pursuant to the Agreement, Changsha Yipeng will utilize Senmiao's data (related to drivers, vehicles and riders) from its historical operating information, to develop an AI-backed data management system to facilitate the collection and analysis of data and ultimately provide online ride-hailing service providers with efficient and safe ways to operate their service vehicles. Along with the development of the project,, both parties will jointly seek necessary financing for its full development and deployment.

AIHS

Senmiao Teams Up With AI Firm to Boost Ride-Hailing Efficiency in China With Smart Data Platform

PROS Holdings Reaffirms Q2 Outlook Of Total Revenues Of $87M-$88M Vs. $89.24M Estimate, And Adjusted EPS Of $0.04-$0.06 Vs. $0.12 Estimate

Wells Fargo analyst Finian O'Shea initiates coverage on Blue Owl Technology Finance Corp. Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTF#NYSE">OTF</a>) with a Equal-Weight rating and announces Price Target of $15.

Initiation

Wells Fargo Initiates Coverage On Blue Owl Technology Finance Corp. Common Stock with Equal-Weight Rating, Announces Price Target of $15

The Federal Reserve is widely expected to maintain its benchmark interest rate in the 4.25%-4.50% range at next week&#8217;s policy meeting, as policymakers weigh recent soft inflation <a href="https://www.benzinga.com/news/politics/25/06/45913481/trump-rips-jerome-powell-over-rates-but-supreme-court-shields-fed-from-firing">data against ongoing uncertainty </a>from President Donald Trump&#8216;s trade policies and demands for aggressive rate cuts.
What Happened: The Federal Reserve will likely keep rates unchanged at its June 17-18 meeting despite recent inflation readings showing consumer and producer prices both increased less than expected in May, reported Reuters. Fed Chair Jerome Powell has indicated the central bank will maintain a &#8220;wait-and-see&#8221; approach amid unresolved trade and budget issues that could impact both inflation and economic growth.
Gregory Daco, chief economist at EY-Parthenon, said, &#8220;Recent Fed commentary has reinforced a wait-and-see approach, with officials signaling little urgency to adjust policy amid increased uncertainty around the economic outlook.&#8221;
Trump has <a href="https://www.benzinga.com/news/politics/25/06/45913481/trump-rips-jerome-powell-over-rates-but-supreme-court-shields-fed-from-firing">demanded the central bank</a> immediately cut its benchmark overnight interest rate by a full percentage point, calling Fed Chair Powell &#8220;one numbskull&#8221; for maintaining current policy. At a White House meeting last month, Powell told the president he would not allow politics to influence monetary policy decisions.
The Fed&#8217;s policy rate has remained in the current range since December, when officials expected to begin a steady series of rate reductions. However, Trump&#8217;s trade policies raised risks of higher inflation and slower growth, complicating the central bank&#8217;s dual mandate of price stability and maximum employment.
See Also: <a href="https://www.benzinga.com/news/politics/25/06/45922022/trump-issues-stark-warning-to-iran-to-make-a-deal-after-israels-strikes-on-nuclear-sites-just-do-it-before-its-too-late">Trump Issues Stark Warning To Iran To &#8216;Make A Deal&#8217; After Israel&#8217;s Strikes On Nuclear Sites: &#8216;Just Do It Before It&#8217;s Too Late&#8217;</a>
Why It Matters: Market participants currently price in expectations for possible rate cuts this year, with recent data showing year-over-year inflation measured by the Fed&#8217;s preferred Personal Consumption Expenditures Price Index running close to the 2% target over the past three months. The unemployment rate has held steady at 4.2% for three consecutive months.
President Trump on Thursday escalated his criticism of Powell, blaming the Federal Reserve chief&#8217;s rate stance for higher <a href="https://www.benzinga.com/topic/national-debt" target="_blank" rel="noreferrer noopener">U.S. debt costs.</a> &#8220;We can&#8217;t get this guy to do it," he said. "And the fake news is saying, ‘Oh if you fired him it would be so bad.' I don&#8217;t know why it would be so bad, but I&#8217;m not going to fire him.&#8221;
The Supreme Court recently <a href="https://www.benzinga.com/25/05/45579414/supreme-court-says-trump-cant-fire-jerome-powellthe-fed-a-uniquely-structured-quasi-private-entity">upheld the Federal Reserve&#8217;s independence</a> from presidential interference, describing it as a &#8220;uniquely structured, quasi-private entity&#8221; that cannot be dismissed without cause. This legal protection shields Powell, whose term ends in May 2026, from Trump&#8217;s repeated threats of removal for not cutting rates aggressively enough.
Minneapolis Fed President Neel Kashkari warned that tariff negotiations &#8220;may take months or years&#8221; to conclude, with potential for &#8220;tit-for-tat tariff increases&#8221; from trading partners. Goldman Sachs analysts lowered recession odds to around 30% but maintained expectations that higher inflation numbers over the summer could sideline rate cuts until December. Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/06/45922274/world-economic-forum-says-gender-equality-is-123-years-away-un-projects-7-trillion-boost-to-global-economy-if-gap-closes">World Economic Forum Says Gender Equality Is 123 Years Away: UN Projects $7 Trillion Boost To Global Economy If Gap Closes</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Poetra.RH On Shutterstock

Comments

Rubrik

Actualités

Dernières nouvelles pour Rubrik (NYSE:RBRK) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL